Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
Latest News

Orchid Pharma receives approval for schizophrenia drug from USFDA

UTI Mutual Fund has picked up 4.45 lakh shares of the company for an average price of Rs 571 per share.

Orchid Pharma receives approval for Aripiprazole Orally-Disintegrating tablets from the US health regulator.

The company in a filing to BSE stated it, “has received ANDA (abbreviated new drug application) approval from USFDA (United States Food and Drug Administration) for Aripiprazole Orally-Disintegrating tablets USP, 10 mg and 15 mg.”

The drug which has received approval is suggested for treatment of symptoms related to psychotic conditions such as schizophrenia and bipolar disorder (manic depression).

Read EquityPandit’s Technical Analysis on Nifty Pharma

Get Daily Prediction & Stocks Tips On Your Mobile